Oral Icotrokinra Hits 63% Response Rate in Phase 2 Ulcerative Colitis Trial

The trial randomized 252 adults to 100 mg, 200 mg, or 400 mg icotrokinra or placebo daily. Primary endpoint was clinical response at week 12 using modified Mayo score; secondary endpoints included clinical remission, symptomatic remission, and endoscopic improvement. All doses met the primary endpoint, with the 400 mg arm also showing statistically higher remission (30% vs 11%) and endoscopic improvement (37% vs 14%). Adverse event rates remained comparable to placebo through week 28, with fewer serious events in active arms.

Icotrokinra is a peptide antagonist of the IL-23 receptor, a pathway already validated by injectable monoclonal antibodies such as guselkumab and risankizumab. The oral route addresses documented adherence gaps in IBD, where injectable biologics show 30-50% discontinuation by year two. The drug retained efficacy in patients who had failed prior therapies, suggesting it may occupy a distinct niche before escalation to JAK inhibitors or surgery.

Phase 3 programs will need to confirm durability beyond 12 weeks, assess corticosteroid-free remission, and compare directly against existing IL-23 agents. Long-term safety monitoring must track infection and malignancy signals seen with other cytokine blockers. If these hurdles are cleared, icotrokinra could expand first-line oral options and reduce reliance on infusions.

Remaining questions include dose-response durability, mucosal healing rates at one year, and performance in biologic-naïve versus refractory populations.